메뉴 건너뛰기




Volumn 4, Issue 2, 2015, Pages 253-267

Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis

Author keywords

AKT; GDF15; Linear model analysis; Ovarian cancer; Platinum resistance

Indexed keywords

CARBOPLATIN; CHECKPOINT KINASE 2; GROWTH DIFFERENTIATION FACTOR 15; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P27; ANTINEOPLASTIC AGENT; CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GDF15 PROTEIN, HUMAN;

EID: 84964694424     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.354     Document Type: Article
Times cited : (22)

References (50)
  • 2
    • 84879079619 scopus 로고    scopus 로고
    • An international assessment of ovarian cancer incidence and mortality
    • Lowe, K. A.. et al., 2013. An international assessment of ovarian cancer incidence and mortality. Gynecol. Oncol., 130:107-114.
    • (2013) Gynecol. Oncol. , vol.130 , pp. 107-114
    • Lowe, K.A.1
  • 3
    • 11844278537 scopus 로고    scopus 로고
    • Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000
    • Bray, F., et al. 2005. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int. J. Cancer 113:977-990.
    • (2005) Int. J. Cancer , vol.113 , pp. 977-990
    • Bray, F.1
  • 4
    • 11844278537 scopus 로고    scopus 로고
    • Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000
    • Bray, F., et al., 2005. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. 113:977-990.
    • (2005) , vol.113 , pp. 977-990
    • Bray, F.1
  • 5
    • 77952315345 scopus 로고    scopus 로고
    • Development of a multimarker assay for early detection of ovarian cancer
    • Yurkovetsky, Z., et al. 2010. Development of a multimarker assay for early detection of ovarian cancer. J. Clin. Oncol. 28:2159-2166.
    • (2010) J. Clin. Oncol. , vol.28 , pp. 2159-2166
    • Yurkovetsky, Z.1
  • 6
    • 48249137385 scopus 로고    scopus 로고
    • Early detection of ovarian cancer
    • Das, P. M., and R. C., Jr. Bast . 2008. Early detection of ovarian cancer. Biomark. Med. 2:291-303.
    • (2008) Biomark. Med. , vol.2 , pp. 291-303
    • Das, P.M.1    Bast, R.C.2
  • 7
    • 0345256652 scopus 로고    scopus 로고
    • Cisplatin: mode of cytotoxic action and molecular basis of resistance
    • Siddik, Z. H. 2003. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279.
    • (2003) Oncogene , vol.22 , pp. 7265-7279
    • Siddik, Z.H.1
  • 8
    • 18244379333 scopus 로고    scopus 로고
    • Cellular processing of platinum anticancer drugs
    • Wang, D., and S. J. Lippard . 2005. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4:307-320.
    • (2005) Nat. Rev. Drug Discov. , vol.4 , pp. 307-320
    • Wang, D.1    Lippard, S.J.2
  • 9
    • 84859771379 scopus 로고    scopus 로고
    • Molecular mechanisms of cisplatin resistance
    • Galluzzi, L., et al. 2012. Molecular mechanisms of cisplatin resistance. Oncogene 31:1869-1883.
    • (2012) Oncogene , vol.31 , pp. 1869-1883
    • Galluzzi, L.1
  • 10
    • 34249321653 scopus 로고    scopus 로고
    • Mechanisms of resistance to cisplatin and carboplatin
    • Stewart, D. J. 2007. Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol. 63:12-31.
    • (2007) Crit. Rev. Oncol. Hematol. , vol.63 , pp. 12-31
    • Stewart, D.J.1
  • 11
    • 85026145371 scopus 로고    scopus 로고
    • Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions
    • Bock, A. J., et al. 2010. Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions. Int. J. Gynecol. Cancer 20:1448-1455.
    • (2010) Int. J. Gynecol. Cancer , vol.20 , pp. 1448-1455
    • Bock, A.J.1
  • 12
    • 77955555369 scopus 로고    scopus 로고
    • Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer
    • Staff, A. C., et al. 2010. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol. Oncol. 118:237-243.
    • (2010) Gynecol. Oncol. , vol.118 , pp. 237-243
    • Staff, A.C.1
  • 13
    • 84871573868 scopus 로고    scopus 로고
    • Macrophage inhibitory cytokine-1: a review of its pleiotropic actions in cancer
    • Khaled, Y. S., E. Elkord, and B. J. Ammori . 2012. Macrophage inhibitory cytokine-1: a review of its pleiotropic actions in cancer. Cancer Biomark. 11:183-190.
    • (2012) Cancer Biomark. , vol.11 , pp. 183-190
    • Khaled, Y.S.1    Elkord, E.2    Ammori, B.J.3
  • 14
    • 67650671369 scopus 로고    scopus 로고
    • Growth-differentiation factor-15 in heart failure
    • Kempf, T., and K. C. Wollert . 2009. Growth-differentiation factor-15 in heart failure. Heart Fail. Clin. 5:537-547.
    • (2009) Heart Fail. Clin. , vol.5 , pp. 537-547
    • Kempf, T.1    Wollert, K.C.2
  • 15
    • 11144353917 scopus 로고    scopus 로고
    • Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers
    • Koopmann, J., et al. 2004. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin. Cancer Res. 10:2386-2392.
    • (2004) Clin. Cancer Res. , vol.10 , pp. 2386-2392
    • Koopmann, J.1
  • 16
    • 0032948894 scopus 로고    scopus 로고
    • MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation
    • Fairlie, W. D., et al. 1999. MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. J. Leukoc. Biol. 65:2-5.
    • (1999) J. Leukoc. Biol. , vol.65 , pp. 2-5
    • Fairlie, W.D.1
  • 17
    • 18744405699 scopus 로고    scopus 로고
    • Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury
    • Zimmers, T. A., et al. 2005. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock 23:543-548.
    • (2005) Shock , vol.23 , pp. 543-548
    • Zimmers, T.A.1
  • 18
    • 2442701601 scopus 로고    scopus 로고
    • Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation
    • Yang, H., et al. 2003. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol. Cancer Ther. 2:1023-1029.
    • (2003) Mol. Cancer Ther. , vol.2 , pp. 1023-1029
    • Yang, H.1
  • 19
    • 0034331055 scopus 로고    scopus 로고
    • Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers
    • Rebbeck, T. R. 2000. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 18(Suppl. 21):100s-103s.
    • (2000) J. Clin. Oncol. , vol.18 , pp. 100s-103s
    • Rebbeck, T.R.1
  • 20
    • 84873413504 scopus 로고    scopus 로고
    • The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer
    • Wang, X., S. J. Baek, and T. E. Eling . 2013. The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. Biochem. Pharmacol. 85:597-606.
    • (2013) Biochem. Pharmacol. , vol.85 , pp. 597-606
    • Wang, X.1    Baek, S.J.2    Eling, T.E.3
  • 21
    • 77954604008 scopus 로고    scopus 로고
    • Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer
    • Mimeault, M., and S. K. Batra . 2010. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J. Cell. Physiol. 224:626-635.
    • (2010) J. Cell. Physiol. , vol.224 , pp. 626-635
    • Mimeault, M.1    Batra, S.K.2
  • 22
    • 41849104687 scopus 로고    scopus 로고
    • Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells
    • Kim, K. K., et al. 2008. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis 29:704-712.
    • (2008) Carcinogenesis , vol.29 , pp. 704-712
    • Kim, K.K.1
  • 23
    • 84858175766 scopus 로고    scopus 로고
    • Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma
    • Corre, J., et al. 2012. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res. 72:1395-1406.
    • (2012) Cancer Res. , vol.72 , pp. 1395-1406
    • Corre, J.1
  • 24
    • 0023111825 scopus 로고
    • Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues
    • Behrens, B. C., et al. 1987. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47:414-418.
    • (1987) Cancer Res. , vol.47 , pp. 414-418
    • Behrens, B.C.1
  • 25
    • 84873740471 scopus 로고    scopus 로고
    • The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells
    • Galavotti, S., et al. 2013. The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene 32:699-712.
    • (2013) Oncogene , vol.32 , pp. 699-712
    • Galavotti, S.1
  • 26
    • 0021023416 scopus 로고
    • Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis
    • Cramer, D. W., W. R., Welch . 1983. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J. Natl Cancer Inst. 71:717-721.
    • (1983) J. Natl Cancer Inst. , vol.71 , pp. 717-721
    • Cramer, D.W.1    Welch, W.R.2
  • 27
    • 28844483193 scopus 로고    scopus 로고
    • HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo
    • Dai, Y., et al. 2005. HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J. Biol. Chem. 280:40066-40073.
    • (2005) J. Biol. Chem. , vol.280 , pp. 40066-40073
    • Dai, Y.1
  • 28
    • 79956226810 scopus 로고    scopus 로고
    • SULFs in human neoplasia: implication as progression and prognosis factors
    • Bret, C., et al. 2011. SULFs in human neoplasia: implication as progression and prognosis factors. J. Transl. Med. 9:72.
    • (2011) J. Transl. Med. , vol.9 , pp. 72
    • Bret, C.1
  • 29
    • 0035971181 scopus 로고    scopus 로고
    • Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α: a new model for anti-estrogen resistance
    • Campbell, R. A., et al. 2001. Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α: a new model for anti-estrogen resistance. J. Biol. Chem. 276:9817-9824.
    • (2001) J. Biol. Chem. , vol.276 , pp. 9817-9824
    • Campbell, R.A.1
  • 30
    • 0036196994 scopus 로고    scopus 로고
    • Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer
    • Meier, C. R., S. Schmitz, and H. Jick . 2002. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22:303-309.
    • (2002) Pharmacotherapy , vol.22 , pp. 303-309
    • Meier, C.R.1    Schmitz, S.2    Jick, H.3
  • 31
    • 70350225568 scopus 로고    scopus 로고
    • Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling
    • Zhao, L., et al. 2009. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res. 69:7696-7703.
    • (2009) Cancer Res. , vol.69 , pp. 7696-7703
    • Zhao, L.1
  • 32
    • 84963044732 scopus 로고
    • Determinants of ovarian cancer risk. I. Reproductive experiences and family history
    • Cramer, D. W., G. B. Hutchison, W. R. Welch, R. E. Scully, and K. J. Ryan . 1983. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J. Natl Cancer Inst.. 71:711-716.
    • (1983) J. Natl Cancer Inst. , vol.71 , pp. 711-716
    • Cramer, D.W.1    Hutchison, G.B.2    Welch, W.R.3    Scully, R.E.4    Ryan, K.J.5
  • 33
    • 61849084730 scopus 로고    scopus 로고
    • p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms
    • Kelly, J. A., M. S. Lucia, J. R. Lambert . 2009. p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms. Cancer Lett. 277:38-47.
    • (2009) Cancer Lett. , vol.277 , pp. 38-47
    • Kelly, J.A.1    Lucia, M.S.2    Lambert, J.R.3
  • 34
    • 0025900804 scopus 로고
    • Pooled analysis of 3 european case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer
    • Negri, E., et al. 1991. Pooled analysis of 3 european case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int. J. Cancer 49:50-56.
    • (1991) Int. J. Cancer , vol.49 , pp. 50-56
    • Negri, E.1
  • 35
    • 84869221003 scopus 로고    scopus 로고
    • Deficient DNA damage signaling leads to chemoresistance to cisplatin in oral cancer
    • Wang, L., et al. 2012. Deficient DNA damage signaling leads to chemoresistance to cisplatin in oral cancer. Mol. Cancer Ther. 11:2401-2409.
    • (2012) Mol. Cancer Ther. , vol.11 , pp. 2401-2409
    • Wang, L.1
  • 36
    • 67649424560 scopus 로고    scopus 로고
    • p21 in cancer: intricate networks and multiple activities
    • Abbas, T., and A. Dutta . 2009. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9:400-414.
    • (2009) Nat. Rev. Cancer , vol.9 , pp. 400-414
    • Abbas, T.1    Dutta, A.2
  • 37
    • 84877280543 scopus 로고    scopus 로고
    • Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance
    • Singh, M., et al. 2013. Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance. BMC Cancer 13:233.
    • (2013) BMC Cancer , vol.13 , pp. 233
    • Singh, M.1
  • 39
    • 73849152723 scopus 로고    scopus 로고
    • Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein
    • Abedini, M. R., et al. 2010. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene 29:11-25.
    • (2010) Oncogene , vol.29 , pp. 11-25
    • Abedini, M.R.1
  • 40
    • 0043016358 scopus 로고    scopus 로고
    • Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells
    • Liu, T., et al. 2003. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res. 63:5034-5040.
    • (2003) Cancer Res. , vol.63 , pp. 5034-5040
    • Liu, T.1
  • 41
    • 0042134847 scopus 로고    scopus 로고
    • Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system
    • Lee, D. H., et al. 2003. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res. 63:4648-4655.
    • (2003) Cancer Res. , vol.63 , pp. 4648-4655
    • Lee, D.H.1
  • 42
    • 33750736082 scopus 로고    scopus 로고
    • Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia
    • Baek, S. J., et al. 2006. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 131:1553-1560.
    • (2006) Gastroenterology , vol.131 , pp. 1553-1560
    • Baek, S.J.1
  • 43
    • 33745957772 scopus 로고    scopus 로고
    • Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth
    • Martinez, J. M., et al. 2006. Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth. J. Pharmacol. Exp. Ther. 318:899-906.
    • (2006) J. Pharmacol. Exp. Ther. , vol.318 , pp. 899-906
    • Martinez, J.M.1
  • 44
    • 41149150219 scopus 로고    scopus 로고
    • The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
    • Chu, I. M., L. Hengst, and J. M. Slingerland . 2008. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 8:253-267.
    • (2008) Nat. Rev. Cancer , vol.8 , pp. 253-267
    • Chu, I.M.1    Hengst, L.2    Slingerland, J.M.3
  • 45
    • 80155151895 scopus 로고    scopus 로고
    • Combined loss of p21waf1/cip1 and p27kip1 enhances tumorigenesis in mice
    • Garcia-Fernandez, R. A., et al. 2011. Combined loss of p21waf1/cip1 and p27kip1 enhances tumorigenesis in mice. Lab. Invest. 91:1634-1642.
    • (2011) Lab. Invest. , vol.91 , pp. 1634-1642
    • Garcia-Fernandez, R.A.1
  • 46
    • 58049216794 scopus 로고    scopus 로고
    • p53 regulates hematopoietic stem cell quiescence
    • Liu, Y., et al. 2009. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 4:37-48.
    • (2009) Cell Stem Cell , vol.4 , pp. 37-48
    • Liu, Y.1
  • 47
    • 84857504660 scopus 로고    scopus 로고
    • Cellular senescence and tumor suppressor gene p16
    • Rayess, H., M. B. Wang, and E. S. Srivatsan . 2012. Cellular senescence and tumor suppressor gene p16. Int. J. Cancer 130:1715-1725.
    • (2012) Int. J. Cancer , vol.130 , pp. 1715-1725
    • Rayess, H.1    Wang, M.B.2    Srivatsan, E.S.3
  • 48
    • 40349116235 scopus 로고    scopus 로고
    • Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor
    • Surowiak, P., et al. 2008. Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor. Histol. Histopathol. 23:531-538.
    • (2008) Histol. Histopathol. , vol.23 , pp. 531-538
    • Surowiak, P.1
  • 49
    • 28544452713 scopus 로고    scopus 로고
    • Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary
    • Bonome, T., et al. 2005. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 65:10602-10612.
    • (2005) Cancer Res. , vol.65 , pp. 10602-10612
    • Bonome, T.1
  • 50
    • 60749137451 scopus 로고    scopus 로고
    • Beyond chemotherapy: targeted therapies in ovarian cancer
    • Yap, T. A., C. P. Carden, and S. B. Kaye . 2009. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat. Rev. Cancer 9:167-181.
    • (2009) Nat. Rev. Cancer , vol.9 , pp. 167-181
    • Yap, T.A.1    Carden, C.P.2    Kaye, S.B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.